Johnson & Johnson maintains 2025 guidance after beating Q2 expectations

Overview

Johnson & Johnson has reaffirmed its full-year guidance after posting stronger-than-expected earnings for Q2 of 2025, driven by solid performance across its Innovative Medicine and MedTech segments. The company reported sales of $23.7bn, marking a 5.8% increase compared to the second quarter of 2024. Net earnings totaled $5.5bn, or $2.29 per share on a diluted basis, representing an 18.7% year-over-year increase. Adjusted earnings per share came in at $2.77, slightly ahead of analyst estimates.

Joaquin Duato, Chairman and Chief Executive Officer, stated: “Today’s strong results reflect the depth and strenght of Johnson & Johnson’s uniquely diversified business operating across both MedTech and Innovative Medicine.”

Q2 2025 vs. Q2 2024:

Sales recorded a value of $23.74bn (+5.8% YoY, +4.6% operational), with broad-based growth across both segments.
Net earnings (GAAP) rose to $5.54bn, compared to $4.69bn in Q2 2024 (+18.2% YoY).
Adjusted net earnings (non-GAAP) totaled $6.70bn, slightly below $6.84bn in Q2 2024 (-2.1% YoY).
Diluted earnings per share (GAAP) were $2.29, up from $1.93 in the prior-year quarter.
Adjusted EPS (non-GAAP) was $2.77, compared to $2.82 in Q2 2024.
Gross profit margin was 67.9%, slightly lower than 69.4% in the same quarter last year, reflecting product mix shifts and amortization expenses.
R&D spending totaled $3.52bn (+2.2% YoY), supporting key pipeline investments and recently acquired assets.
Effective tax rate (GAAP) was 14.7%, improved from 18.5% in Q2 2024 due to favorable tax items.

Innovative Medicine

Revenue increased to $15.20bn (+4.9% YoY, +3.8% operational).
Oncology revenue reached $6.31bn (+24.0% YoY), driven by DARZALEX – $3.54bn (+23.0% YoY) and some strong contributions from CARVYKTI and RYBREVANT.
Immunology revenue declined to $3.99bn (-15.4% YoY), due to biosimilar competition and loss of exclusivity for STELARA.
Neuroscience revenue rose to $2.05bn (+15.1% YoY).
Cardiovascular, Metabolism & Other revenue totaled $930m (+4.2% YoY), led by XARELTO growth.

MedTech

Revenue grew to $8.54bn (+7.3% YoY, +6.1% operational).
Cardiovascular revenue surged to $2.31bn (+23.5% YoY).
Electrophysiology increased to $1.47bn (+11.0% YoY).
Orthopaedics revenue was $2.31bn (-0.3% YoY), impacted by market and product exits.
Surgery revenue reached $2.56bn (+2.7% YoY), with growth in advanced and general surgical products.
Vision revenue rose to $1.37bn (+6.5% YoY), supported by strong performance in both contact lenses and surgical devices.

Following a strong first half of the year, Johnson & Johnson maintained its full-year guidance for 2025. The company expects adjusted operational sales between $92.7bn and $93.1bn and adjusted EPS in the range of $10.63 to $10.73. The company emphasized its commitment to pipeline advancement in oncology, neuroscience, and immunology, while leveraging its MedTech platforms and recent acquisitions to enhance global competitiveness. Johnson & Johnson also noted it remains focused on delivering value through disciplined capital allocation and long-term innovation strategies.

Technically, Johnson & Johnson (JNJ) is currently showing signs of moderate bullish momentum. Following the release of quarterly results, the stock was trading above its 50-day simple moving average, which could suggest an improvement in investor sentiment and a potential trend reversal. At the time of our analysis, the RSI was at 72.36, approaching overbought territory, indicating that the stock could face near-term resistance. However, this level also reflects increasing buying interest. Given the stock’s historical pattern of sideways movement and setbacks over the past year, a sustained move above the recent high near $168 could serve as a key signal for further upside.